Taking the notice of supply of the counterfeit injection Rhophylac used by patients of blood disorders, the Drug Regulatory Authority of Pakistan (DRAP) has banned its sale in the market and usage.
The proscribed injection Rhophylac is a medication used for anti-D immunoglobulin.
The DRAP in an additional alert regarding the product has advised to avoid the use of the human anti-D immunoglobulin drug.
A provincial drug inspector and a Karachi based pharmaceutical company had communicated the information regarding counterfeit injections.
This is not shortage of original Rhophylac injection and is available in pharmacies across the country. The counterfeit injection samples are marked with incorrect information.
The sample injections have been labeled with two different batch numbers, and the bar code also corresponds to a different batch number.
Usage of counterfeit injections could cause severe health issues. DRAP has also instructed the national regulatory field force to increase monitoring. The regulatory team is to confiscate the mentioned Rhophylac batch from the markets.
